Moderna’s mRNA candidate picked for FDA’s Operation Warp Speed for rare diseases

Moderna is joining another Operation Warp Speed initiative — this time, for rare diseases.

The biotech’s mRNA candidate for a protein and lipid metabolism disorder was …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Medacta Hosts Inaugural Capital Markets Day, Showcasing Responsible Innovation and Effective Growth Strategy – Biotech Investments

Medacta Group SA / Key word(s): Miscellaneous Medacta Hosts Inaugural Capital Markets Day, Showcasing Responsible Innovation and Effective Growth Strategy 30.09.2024 / 12:00 CET/CEST MEDIA

October 1, 2024

Eli Lilly reveals two-year data for experimental eczema treatment after FDA roadblock

Eli Lilly is bolstering the case for its experimental eczema treatment lebrikizumab with a first look at how patients fared after two years of maintenance

October 21, 2023

Researchers design one-step procedure for improving effective of adoptive cell immunotherapy against solid tumors

Researchers developed a one-step method to engineer multifunctional M1 phenotype macrophages.

August 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.